NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) announces the completion of its all-stock combination with Anywhere Real Estate Inc. Following the merger, the two companies are comin
Compass Pathways plc experienced an >80% rally since my last 'Hold' rating. CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Recent app
Compass (COMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) (the "Company"), today announced the pricing of its offering of $850.0 million in aggregate principal amount of convertible senior no
On Jan. 7, 2026, investors weighed a massive notes deal, raised guidance, and an approved merger reshaping this real estate platform.
WESTPORT, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle-market branded consumer and industrial businesses, ann
NEW YORK and MADISON, N.J., Jan. 7, 2026 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass") and Anywhere Real Estate Inc. (NYSE: HOUS) ("Anywhere") announce that stockholders of each company vote

Compass and Anywhere Clear a Key Merger Hurdle

10:05am, Wednesday, 07'th Jan 2026
Two of the nation's largest real estate brokerages are one step closer to combining.
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) (the "Company") announces that it intends to offer (the "Offering"), subject to market and other conditions, $750.0 million in aggrega
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announc

Compass Therapeutics Provides Corporate Update

08:00am, Tuesday, 06'th Jan 2026
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced toda
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
WESTPORT, Conn., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of D
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE